Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients

Table 6

Hospitalization course and engraftment: comparison between poor and good mobilizers.

	Median hospital stay (range)	Patients with proven infections during hospital stay, n*	Median days to AGC ≥ 500/mm^3 (range)	Median days to PLT >20 × 10^3/mm^3 (range)
MM
Poor mobilizers (𝑛=8); Good mobilizers (𝑛=10)	19 (15–25); 17 (16–24)	4; 5	14 (12–15); 12 (10–15)	13 (11–46); 12.5 (10–20)
Lymphoma
Poor mobilizers (𝑛=9); Good mobilizers (𝑛=15)	22 (19–52); 22 (18–30)	2; 6	12 (11–33); 12.5 (10–21)**	24 (17–58); 16 (11–240)***

*Infections include bacteremias, pneumonia, clostridium difficile colitis, neutropenic colitis, and fungal infection.
**One patient died during engraftment.
***In addition to the patient who died during engraftment, one patient never reached platelet recovery until death.
NOTE: no significant statistical differences in any of the above categories between poor mobilizers and control good mobilizers.